GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

RVU-120 is under clinical development by Ryvu Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II drugs for Anemia have a 53% phase transition success rate (PTSR) ...

You’re more likely to develop anemia if you also have diabetes or are on dialysis treatment. Tell your doctor if you experience symptoms of anemia so you can start treatment before it gets worse.

Anemia is highly prevalent in patients with chronic heart failure (HF) and is associated with poor clinical outcomes. Multiple mechanisms contribute to anemia in chronic HF, and subnormal ...

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

Iron Deficiency Anemia Treatment Market 2024 - Global & India industry Analysis, Size, Share, Growth, Trends, and Forecast, 2030 WILMINGTON, DE, UNITED STATES, December 17, 2024 /EINPresswire ...

As per the National Heart, Lung, and Blood Institute (NHLBI), one of the main causes of iron deficiency anemia is blood loss.

Luspatercept's safety profile was consistent with previous studies, with no serious treatment-emergent adverse events ...

Opens in a new tab or window Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment model for gene-based sickle cell anemia ...

It is also used in the treatment of various types of anemia caused by chemotherapy. Increasing Prevalence of Anemia and Osteoporosis: Rise in global incidence of anemia and osteoporosis is driving the ...

During a Case-Based Roundtable® event, Andrew Kuykendall, MD, discussed treatment for a 68-year-old patient with intermediate ...